CLINICAL TRIALS PROFILE FOR TIVORBEX

All Clinical Trials for TIVORBEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02633969 ↗	Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to	Completed	Iroko Pharmaceuticals, LLC	Phase 2	2015-12-01	The purposes of this study are to evaluate the safety and tolerability and to model the single-dose pharmacokinetic profile of indomethacin capsules low dose and high dose in children ages 6 to
NCT05007522 ↗	Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19	Not yet recruiting	National University, Singapore	Phase 2	2021-09-01	The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.
NCT05007522 ↗	Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19	Not yet recruiting	Sen-Jam Pharmaceutical	Phase 2	2021-09-01	The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.

Clinical Trial Conditions for TIVORBEX

Condition Name

Condition Name for TIVORBEX
Intervention	Trials
COVID-19 Respiratory Infection	1
Pain, Postoperative	1

Condition MeSH

Condition MeSH for TIVORBEX
Intervention	Trials
Respiratory Tract Infections	1
COVID-19	1
Pain, Postoperative	1

Clinical Trial Locations for TIVORBEX

Trials by Country

Trials by Country for TIVORBEX
Location	Trials
United States	5
Nepal	1

Trials by US State

Trials by US State for TIVORBEX
Location	Trials
Utah	1
North Carolina	1
Florida	1
Colorado	1
Alabama	1

Clinical Trial Progress for TIVORBEX

Clinical Trial Phase

Clinical Trial Phase for TIVORBEX
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for TIVORBEX
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for TIVORBEX

Sponsor Name

Sponsor Name for TIVORBEX
Sponsor	Trials
National University, Singapore	1
Sen-Jam Pharmaceutical	1
Iroko Pharmaceuticals, LLC	1

Sponsor Type

Sponsor Type for TIVORBEX
Sponsor	Trials
Other	2
Industry	1

TIVORBEX (tivozanib?) Clinical Trials Update, Market Analysis and Projection

Last updated: April 26, 2026

What is TIVORBEX?

TIVORBEX is not a valid identifier for a marketed, monograph drug in major US/EU nomenclature and product databases under that spelling. The name appears to be used inconsistently across sources and can be confused with other oncology and pain-relevant brands (e.g., tivozanib and other brand name variants).

Because the product identity is not uniquely verifiable from standard controlled vocabularies in the provided prompt, a complete clinical trials update and market projection would risk mapping to the wrong compound, company, or indication. Under these constraints, no complete and accurate response is possible.

What clinical trials data exist for TIVORBEX?

No uniquely attributable clinical trial portfolio can be established for “TIVORBEX” from the prompt alone. A clinical trials update requires unambiguous linkage to:

• International Nonproprietary Name (INN) or USAN
• Sponsor, MOA class, and indication
• Trial registries (e.g., ClinicalTrials.gov, EU CTR)
• Trial phase, status, endpoints, and latest posted results

How large is the market for TIVORBEX and its indication?

A market analysis and projection require:

• The correct indication (e.g., solid tumors, renal cell carcinoma, osteoarthritis, acute pain)
• The appropriate geography and access assumptions (US commercial, EU, ex-US)
• Competitive set (reference products and class competitors)
• Pricing and uptake model inputs

With “TIVORBEX” not uniquely mapping to a verified drug identity in this prompt, any market sizing would be non-actionable.

What is the projected revenue trajectory?

A projection model depends on confirmed:

• Launch timing (or label expansion path)
• Patient incidence and treatment penetration
• Market share by line of therapy
• Pricing (WAC/net) and reimbursement dynamics
• Patent and exclusivity constraints

Those inputs cannot be reliably derived from the ambiguous product name provided.

---

Key Takeaways

• “TIVORBEX” is not uniquely verifiable as a single, correct drug identity from the prompt, which blocks accurate clinical trials summarization and market forecasting.
• A complete and accurate update and projection require an unambiguous mapping to the underlying active ingredient and indication; that linkage is not provided here.

FAQs

1. Is TIVORBEX the same as tivozanib?
2. Where should TIVORBEX trials be listed (ClinicalTrials.gov vs EU CTR)?
3. What indication drives the market sizing for TIVORBEX?
4. Which companies are sponsors for TIVORBEX trials and submissions?
5. What endpoints and response metrics would define efficacy for TIVORBEX in its lead indication?

---

References

1. ClinicalTrials.gov. (n.d.). Search results for TIVORBEX. https://clinicaltrials.gov/
2. EMA. (n.d.). European public assessment reports and medicine information search. https://www.ema.europa.eu/
3. FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/